CD19 and acute lymphoblastic leukemia: In an exploratory study, Dufva et al. screened 526 compounds that spanned several functional classes such as conventional chemotherapy agents, kinase inhibitors, and apoptotic modulators in order to identify inhibitors and enhancers of CD19-targeting CAR T cytotoxicity against B-acute lymphoid leukemia (B ALL) [20].